CONCLUSIONS
At present, the treatment for NARDS
is mainly PS replacement therapy and ad adjunctive supportive therapy.
Budesonide is a powerful local anti-inflammatory drug, and a large
number of animal and clinical trials have demonstrated that the
utilization of budesonide could reduce the incidence of BPD, duration of
assisted ventilation, and hospitalization. Therefore, it is reasonable
to suppose that budesonide may be an effective drug for the treatment of
NARDS. This review summarizes the current state of research on the
effects of budesonide in ARDS in terms of clinical aspects and related
mechanisms; our findings may provide new insights for clinical
application. However, questions remain regarding the possible mechanisms
of budesonide in the treatment of NARDS. Further clinical and
experimental data are still needed to demonstrate the safety and
efficacy of budesonide in the treatment of NARDS.